BroadOak Logo

BroadOak Increases Investment in Halo Labs

BroadOak joined Agilent Technologies, a global leader in life sciences and diagnostics, to increase its investment in Halo Labs as part of the company’s Series C round of growth financing.

Halo Labs uses state-of-the-art optics and image processing to support drug development. The funding will help Halo Labs grow its product and solutions portfolio for pharmaceutical researchers, enabling them to quickly and efficiently move new therapies from the laboratory to clinics.

The full press release is below.

Halo Labs Completes $6M Series C Growth Financing

Halo Labs Forms Partnership with Agilent Technologies in Series C Funding

BURLINGAME, CA – July 11, 2022 – Halo Labs, a leading life science instrumentation company announced it has raised $6M in series C financing. The round was led by Agilent Technologies Inc. and includes participation from existing investors Research Corporation Technologies, Broad Oak Capital Partners, BioAdvance, and members of the Board of Directors and senior management.

This new funding will be used for continued commercialization of Halo Labs’ Aura™ platform, increasing manufacturing capacity and developing innovative new products to meet the current and new needs of pharmaceutical researchers.

“For the past two years, Halo Labs has deployed an aggressive growth strategy and has raised the bar for innovation in our market,” said Rick Gordon, CEO of Halo Labs. “The fact that we were able to close on a funding round in the current economic environment demonstrates the success of that strategy. Our instruments have been adopted by virtually every major biopharmaceutical company and are now one of the leading tools in cell and gene therapy. With this capital, we will continue our current trajectory and scale our business in some exciting new directions. We are excited to have Agilent as a partner in that journey.”

First launched in 2017, Aura from Halo Labs has disrupted pharmaceutical product development by combining multiple stability, quality, and safety assays into one instrument. Now available in six different models, representing tools specific for different therapeutic modalities and development stages, Aura instruments give pharmaceutical scientists access to an unprecedented amount of data in a matter of minutes, allowing for new therapies to move from the lab to the clinic faster and more safely.

Original Press Release